SEC Form 4 · accession 0001777517-26-000002
Olema Pharmaceuticals, Inc. · OLMA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
G. Walmsley Graham
Director
Period of report
Jun 18, 2026
Accepted (ET)
Jun 23, 2026 · 5:21 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001750284
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $9.51 | Jun 18, 2026 | A | 29,500 | A | — | Jun 18, 2036 | Common Stock | 29,500 | 29,500 | D |
Explanation of responses
- F1The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.